J&J’s nipocalimab meets primary endpoint in Phase II JASMINE study

J&J has reported that its monoclonal antibody, nipocalimab, met the primary endpoint in the Phase II JASMINE study by reducing disease activity in adults with moderate-to-severe SLE. The study is said to be the first to demonstrate efficacy for FcRn inhibition in SLE. Nipocalimab targets FcRn to cut pathogenic IgG autoantibody levels and immune complexes, reducing SLE-related inflammation. Credit: StanislavSukhin / Shutterstock.com. Johnson & Johnson (J&J) has reported that its monoclonal antibody, nipocalimab, met the primary endpoint in the Phase II JASMINE study by reducing disease activity in adults with moderate-to-severe systemic lupus erythematosus (SLE). The results were presented as…

Source: Clinical Trials Arena